iPSC Repository of Pediatric Cardiovascular Disease


Report Abuse


Obtain blood samples for generation and maintenance of induced pluripotent stem cells (iPSCs) and genomic/DNA sequencing for biomedical research that will improve the understanding and treatment of pediatric cardiovascular disease

Study Overview

Start Date
July 2, 2021
Completion Date
December 31, 2025
Date Posted
September 22, 2022
Accepts Healthy Volunteers?


Full Address
Nationwide Children's Hospital
Columbus, Ohio 43205, United States


Study Population
Any individual with or without pediatric cardiovascular disease
Eligibility Criteria
Inclusion Criteria:

The subjects must have the diagnosis of cardiovascular disease
The subject must have a syndrome associated with cardiovascular disease
The subject must be related to an individual in cohort 1 or 2
The subject is considered a control and does not fall into any of the other cohorts

Exclusion Criteria:


Study Contact Info

Study Contact Name
Jade F Hayden, BSN
Study Contact Phone

Contact Listings Owner Form

iPSC Repository of Pediatric Cardiovascular Disease 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
FDA Regulated Device?
Detailed Description
Human induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell which can be generated from easily accessible patient cells, such as peripheral blood mononuclear cells and skin fibroblasts. As iPSCs are epigenetically reprogrammed from somatic cells, they retain all genetic information of the affected patients, thus providing an ideal model for studying the contribution of genetic variation to pediatric cardiovascular disease. In addition, human iPSCs can be differentiated into cardiomyocytes, endothelial cells, smooth muscle cells and cardiac fibroblasts, which are major affected cell types in the heart responsible for cardiovascular disease. Therefore, patient-specific iPSCs possess great promise in modeling pediatric cardiovascular disease, discovering novel drugs and prospective cell regeneration therapy.

The DNA from these patients will be analyzed for point mutations, rare sequence variations, single nucleotide polymorphisms in known cardiac development genes or for chromosomal copy number changes by using state of the art genetic approaches.
NCTid (if applicable)